In vitro study reveals enhanced complement-mediated killing of antibody-resistant tumor cells by targeting surface C4d, suggesting a strategy to amplify cancer immunotherapy efficacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Budka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: